VBI Vaccines Reports Positive Outcome from Phase III Pre-IND Discussions with the FDA for Hepatitis B Vaccine, Sci-B-Vac(TM)
June 19, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 19, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation...
VBI Vaccines to Present at Jefferies 2017 Global Healthcare Conference
June 05, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - June 5, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation...
VBI Vaccines Provides Update on its Congenital CMV Phase I Clinical Study
May 02, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - May 2, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") today provided an update on its cytomegalovirus ("CMV") Phase I clinical study,...
VBI Vaccines to Present Updates on Multiple Programs at the World Vaccine Congress
April 05, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - April 5, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present updates on two of its programs at the World Vaccine...
VBI Vaccines Appoints Avi Mazaltov as Global Head of Manufacturing and SciVac General Manager; Rehovot, Israel Site
March 30, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - March 30, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") and SciVac Ltd. ("SciVac"), a wholly owned subsidiary of VBI, are pleased to...
VBI Vaccines Receives Positive Response from Health Canada's Initial Evaluation of the Proposed Sci-B-Vac Phase III Clinical Program
February 22, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 22, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") announced today that the Biologics and Genetic Therapies Directorate (BGTD) of...
VBI Vaccines Receives Positive EMA Scientific Advice Regarding Sci-B-Vac(TM) Phase III Clinical Study
February 07, 2017 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Feb. 7, 2017) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI") announced today the receipt of positive Scientific Advice from the Committee for...
VBI Vaccines Closes $23.6 Million Financing from Perceptive Advisors
December 06, 2016 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Dec. 6, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV) (TSX:VBV) ("VBI"), a clinical-stage biopharmaceutical company developing infectious disease and...
VBI Vaccines Reports Rapid Seroprotection Results from an Interim Analysis of a Phase IV Postmarketing Study of its Sci-B-Vac(TM) Hepatitis B Vaccine
November 14, 2016 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Nov. 14, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") today reported interim results from an ongoing Phase IV postmarketing study to...
VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting
November 10, 2016 08:30 ET
|
VBI Vaccines Inc.
CAMBRIDGE, MASSACHUSETTS--(Marketwired - Nov. 10, 2016) - VBI Vaccines Inc. (NASDAQ:VBIV)(TSX:VBV) ("VBI") is scheduled to present at the Society of Neuro-Oncology Annual Meeting on...